The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.

New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”

In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing health care by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.

Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.